MannKind Corp Asset Resilience Ratio
MannKind Corp asset resilience ratio. MannKind Corp (MNKD) has an Asset Resilience Ratio of 7.95% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MNKD defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of MannKind Corp (2002–2025)
Asset resilience ratio of MannKind Corp from 2002 to 2025. This chart shows how MannKind Corp's Asset Resilience Ratio has changed over time. Read debt load of MannKind Corp for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down MannKind Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see MannKind Corp (MNKD) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $58.20 Million | 7.95% |
| Total Liquid Assets | $58.20 Million | 7.95% |
Asset Resilience Insights
- Limited Liquidity: MannKind Corp maintains only 7.95% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
MannKind Corp Industry Peers by Asset Resilience Ratio
Compare MannKind Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
MannKind Corp Asset Resilience Ratio by Year (2002–2025)
MannKind Corp asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for MannKind Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.18% | $96.46 Million | $792.18 Million | -26.14pp |
| 2024-12-31 | 38.32% | $150.92 Million | $393.84 Million | +26.40pp |
| 2023-12-31 | 11.91% | $56.62 Million | $475.20 Million | -22.32pp |
| 2022-12-31 | 34.23% | $101.08 Million | $295.28 Million | +9.34pp |
| 2021-12-31 | 24.89% | $79.93 Million | $321.16 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $108.61 Million | -- |
| 2019-12-31 | 21.32% | $19.98 Million | $93.72 Million | +15.63pp |
| 2017-12-31 | 5.69% | $4.81 Million | $84.58 Million | +5.36pp |
| 2016-12-31 | 0.33% | $350.00K | $107.06 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $126.41 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $394.44 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $258.65 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $251.31 Million | -- |
| 2011-12-31 | 0.26% | $515.00K | $199.55 Million | -1.32pp |
| 2010-12-31 | 1.58% | $4.37 Million | $277.26 Million | +0.58pp |
| 2009-12-31 | 1.00% | $2.48 Million | $247.40 Million | -5.67pp |
| 2008-12-31 | 6.67% | $18.84 Million | $282.46 Million | -14.99pp |
| 2006-12-31 | 21.66% | $116.92 Million | $539.74 Million | -17.57pp |
| 2005-12-31 | 39.23% | $89.60 Million | $228.37 Million | +32.17pp |
| 2004-12-31 | 7.06% | $11.55 Million | $163.48 Million | +5.61pp |
| 2003-12-31 | 1.45% | $1.82 Million | $125.88 Million | -9.18pp |
| 2002-12-31 | 10.63% | $11.13 Million | $104.77 Million | -- |
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve… Read more